Advanced circulatory support in oncologic patients with refractory cardiorespiratory failure.

Area of Science:

• Oncology
• Critical Care Medicine
• Cardiopulmonary Support

Background:

• Intensive care unit (ICU) populations are evolving with more cancer patients experiencing refractory cardiorespiratory failure.
• Extracorporeal Circulatory Support (ECLS), including ECMO, is now considered for indications beyond traditional use in these complex patients.
• This presents unique clinical, physiological, and ethical challenges in oncologic critical care.

Purpose of the Study:

• To describe the current role of ECLS in critically ill cancer patients with solid and hematologic malignancies.
• To integrate evidence on ECLS indications, patient selection, physiological aspects, complications, and outcomes.
• To frame ECLS as a selective intervention for this patient group.

Main Methods:

• Review of current evidence regarding ECLS use in critically ill cancer patients.
• Analysis of data on indications, patient selection criteria, and physiological considerations.
• Evaluation of reported complications and patient outcomes.

Main Results:

• Study findings are heterogeneous, with consistently limited observed outcomes reported.
• ECLS use in oncologic patients is associated with significant complexities and challenges.
• Limited data exists, emphasizing the need for careful interpretation of results.

Conclusions:

• ECLS in critically ill cancer patients should be a highly selective intervention.
• Decision-making requires careful consideration of emerging cohort data.
• Multidisciplinary evaluation, oncologic trajectory, organ failure reversibility, and patient-centered goals are crucial for guiding ECLS use.